TBPH - Theravance Biopharma, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.44
|
Rev Est: $43.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.50
DETAILS
HIGH:
$40.00
LOW:
$27.00
MEDIAN:
$33.50
CONSENSUS:
$33.50
UPSIDE:
75.76%
Market Cap:
965.82M
Volume:
348,909
Avg Volume:
459,461
52 Week Range:
7.9-21.03
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.16
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
KY
Employees:
97
IPO Date:
2014-05-16
EPS (TTM):
-1.15
P/E Ratio:
-8.15
Revenue (TTM):
64.38M
Total Assets:
354.16M
Total Debt:
49.82M
Cash & Equiv:
37.80M
Rev Growth (5Y):
-2.6%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-13.1%
Debt/Equity:
0.28
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $0.04 | $-0.03 | +233.3% | $20.0M | $43.1M | -53.6% |
| 2025-08-12 | $-0.08 | $-0.14 | +42.9% | $26.2M | $18.7M | +39.9% |
| 2025-05-08 | $-0.17 | $-0.11 | -54.5% | $15.4M | $16.1M | -4.4% |
| 2025-02-26 | $-0.05 | $-0.05 | 0.0% | $18.8M | $17.1M | +9.7% |
| 2024-11-12 | $-0.06 | $-0.10 | +40.0% | $16.9M | $27.3M | -38.2% |
| 2024-08-05 | $-0.13 | $-0.09 | -44.4% | $14.3M | $15.4M | -7.7% |
| 2024-05-13 | $-0.09 | $-0.19 | +52.6% | $14.5M | $14.0M | +3.9% |
| 2024-02-26 | $0.03 | $0.04 | -14.4% | $17.6M | $17.7M | -0.7% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.38M | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M | 226,000 |
| Net Income | (56.42M) | (55.19M) | 872.13M | (199.43M) | (278.02M) | (236.46M) | (215.52M) | (285.40M) | (190.67M) | (182.22M) | (237.04M) | (156.28M) |
| EPS | -1.15 | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.92 |
| Total Assets | 354.16M | 382.00M | 607.40M | 374.82M | 469.06M | 408.83M | 560.24M | 441.40M | 639.25M | 300.12M | 337.77M | 25.18M |
| Total Debt | 49.82M | 49.16M | 52.16M | 669.52M | 676.26M | 510.53M | 454.35M | 223.75M | 222.68M | 0 | 0 | 0 |
| Cash & Equivalents | 37.80M | 39.55M | 298.17M | 89.96M | 81.47M | 58.06M | 378.02M | 88.98M | 344.71M | 112.71M | 89.22M | 0 |
| Operating Cash Flow | (11.54M) | (27.00M) | (186.99M) | (207.86M) | (250.40M) | (238.20M) | (112.87M) | (201.05M) | (98.99M) | (168.86M) | (175.16M) | (120.96M) |
| Free Cash Flow | (11.87M) | (29.48M) | (187.56M) | (211.26M) | (257.02M) | (241.37M) | (120.11M) | (203.46M) | (101.12M) | (171.50M) | (178.26M) | (123.69M) |
| FCF per Share | -0.24 | -0.53 | -2.55 | -3.04 | -4.12 | -4.34 | -2.23 | -3.89 | -2.26 | -5.02 | -5.61 | -3.90 |
| Book Value | 175.54M | 213.00M | 441.80M | (338.57M) | (303.75M) | (223.84M) | (51.59M) | 115.18M | 350.23M | 243.06M | 289.79M | (17.04M) |
| Cash & ST Investments | 88.35M | 102.43M | 327.48M | 173.47M | 292.94M | 280.83M | 505.28M | 348.57M | 501.10M | 172.43M | 306.01M | 0 |
| ROC Equity | -0.32 | -0.26 | 1.97 | N/A | N/A | N/A | N/A | -2.48 | -0.54 | -0.75 | -0.82 | N/A |